| NCT ID | NCT05406037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Mucorales Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-11-29 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-11-29 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization. Prompt initiation of adequate antifungal therapy is critical for treating mucormycosis. Early diagnostic is therefore essential. The presence in the Mucorales' cell wall of uncommon monosaccharides open interesting perspectives for the development of specific diagnostic biomarkers. This study evaluate a diagnostic test for mucormycosis in a cohort of patients with MM and in control groups (high-risk patients without MM and patients with another IFI).
Eligibility Criteria
Inclusion Criteria: * Men and women * Age : Children and adults from 3 to 64 years old (18 to 64 for controls) * In patients whose consent has been collected after information. In the case of children, information on the study will be given to the holders of parental authority and then to the child to obtain their consent. * Patient social insured * Specific medical conditions : 1. For the case group : Any patient hospitalized in one of the departments of the University Hospital of Lille, in which the diagnosis of mucormycosis was conducted on the following criteria: * Conventional mycology data and / or * Positivity of q-PRC and / or * Anatomopathologic diagnosis Associated with a compatible clinical situation 2. For the control group 1 Patient assessed for hematopoietic stem cell transplantation, considered at risk for IFI but for whom the pre-transplantation review will have excluded an ongoing infection 3. For control group 2 Any patient hospitalized in a department of Lille University Hospital, in which the diagnosis of disseminated candidiasis or invasive pulmonary aspergillosis has been made according to specific classifications (EORTC/MSG criteria, AspICU criteria) Exclusion Criteria: * Patients for whom the inclusion criteria are not met * Co-infection mucormycosis/other IFI
Contact & Investigator
Marjorie CORNU, MD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT05406037 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 64 Years, studying Mucorales Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05406037 currently recruiting?
Yes, NCT05406037 is actively recruiting participants. Contact the research team at marjorie.cornu@chru-lille.fr for enrollment information.
Where is the NCT05406037 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT05406037 clinical trial?
NCT05406037 is sponsored by University Hospital, Lille. The principal investigator is Marjorie CORNU, MD at University Hospital, Lille. The trial plans to enroll 100 participants.